New onset refractory status epilepticus: Long‐term outcomes beyond seizures
Epilepsia · 2025-04 · 66 (4) · 988-1005
DOI: 10.1111/epi.18267 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Epilepsia, online erschienen am 18.01.2025. Verfasst von Poul H Espino und 31 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Neurological Sciences, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada. Hauptthemen laut MEDLINE: Status Epilepticus, Drug Resistant Epilepsy. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
We propose and prioritize important outcome domains that should be considered for future research investigating long‐term outcomes (LTO) after new onset refractory status epilepticus (NORSE). The study was led by the international NORSE Institute LTO Working Group. First, literature describing the LTO of NORSE survivors was identified using a PubMed search and summarized to identify knowledge gaps. Subsequently, a consensus‐building process was performed to prioritize and rank important LTO domains for further research. The prioritization of LTO domains was qualitative, enabling the expert panel to generate ideas, share opinions, and provide reasons for the rankings. A second round took place to allow expansion and agreement regarding specific details for each domain. Outcomes were classified into eight main domains: (1) Function: Neuropsychological, Neurological (other than seizures), and Psychiatric (mood and behavior); (2) Quality of Life; (3) Epilepsy; (4) Nonneurological (medical); (5) Social; (6) Caregiver Burden; (7) Long‐Term Mortality; and (8) Health Care System Impact. In addition, the working group suggested obtaining outcome measures for each domain at 6 months and 1 year after discharge and annually thereafter until stability has been reached. There are no currently established time frames set for when LTO in NORSE begin or plateau, and previously there existed no consensus regarding which LTO should be considered. This consensus process identifies and recommends NORSE LTO domains that should be considered in future research studies to provide more consistent results that can be compared between studies. Survivors of NORSE should be evaluated serially and at fixed points over time to maximize our understanding of the recovery trajectory for all LTO domains. Establishing reliable and standardized data describing LTO (beyond seizures) after NORSE will support discussions with families during the acute stages, prognostication, the development of targeted management strategies for survivors, and future comparative research globally helping to identify biomarkers that may predict LTO.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Neurological Sciences, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
- Section of Child Neurology, Department of Pediatrics, Children's Hospital Colorado, University of Colorado, Aurora, Colorado, USA.
- Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- Department of Neurology, Johns Hopkins Hospital, Baltimore, Maryland, USA.
- Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.
- Department of Neurology, Children's Hospital of Wisconsin, Milwaukee, Wisconsin, USA.
ORCID-Profile: Poul H Espino, Krista Eschbach, Leah J Blank, Mackenzie C Cervenka, Raquel Farias-Moeller, Hiba A Haider, Lawrence J Hirsch, Soon-Tae Lee, Alexandria E Melendez-Zaidi, Vincent Navarro, Elena Pasini, Gitta Reuner, Coral M Stredny, Adam Strzelczyk, Olga Taraschenko, Andreas van Baalen, Ronny Wickström, Jiyeoun Yoo, Teneille E Gofton
Zitieren
APA
Espino, P. H., Eschbach, K., Blank, L. J., Cervenka, M. C., Muscal, E., Farias-Moeller, R., Gilmore, E. J., Gopaul, M. T., Haider, H. A., Hanin, A., Hirsch, L. J., Kellogg, M. A., Kluger, G., Lee, S. T., Melendez-Zaidi, A. E., Navarro, V., Oliger, A. C., Pasini, E., Reuner, G., …, & Gofton, T. E. (2025). New onset refractory status epilepticus: Long‐term outcomes beyond seizures. Epilepsia, 66(4), 988-1005. https://doi.org/10.1111/epi.18267
Vancouver
Espino PH, Eschbach K, Blank LJ, Cervenka MC, Muscal E, Farias-Moeller R, et al. New onset refractory status epilepticus: Long‐term outcomes beyond seizures. Epilepsia. 2025;66(4):988-1005. doi:10.1111/epi.18267
BibTeX
@article{Espino2025,
author = {Espino, Poul H and Eschbach, Krista and Blank, Leah J and Cervenka, Mackenzie C and Muscal, Eyal and Farias-Moeller, Raquel and Gilmore, Emily J and Gopaul, Margaret T and Haider, Hiba A and Hanin, Aurelie and Hirsch, Lawrence J and Kellogg, Marissa A and Kluger, Gerhard and Lee, Soon-Tae and Melendez-Zaidi, Alexandria E and Navarro, Vincent and Oliger, Audrey C and Pasini, Elena and Reuner, Gitta and Sharpe, Cynthia M and Sheikh, Zubeda B and Steigleder, Leon and Steriade, Claude and Stredny, Coral M and Strzelczyk, Adam and Taraschenko, Olga and van Baalen, Andreas and Vinette, Sarah A and Wickström, Ronny and Wong, Nora W and Yoo, Jiyeoun and Gofton, Teneille E},
title = {New onset refractory status epilepticus: Long‐term outcomes beyond seizures},
journal = {Epilepsia},
year = {2025},
volume = {66},
number = {4},
pages = {988--1005},
doi = {10.1111/epi.18267}
}
EUVIMED